Xarelto | Rivaroxaban 50 Mg Breastfeeding
American Academy of Pediatrics and other medical experts exclusively recommend to breastfeed the baby for first 6 months. Once you introduce baby to other foods it is recommended to breastfeed for at least first year of babys life. Taking medication while breastfeeding could be tricky as most drugs pass in breast milk. In this article we will evaluate Xarelto | Rivaroxaban 50 Mg for its safety in breastfeeding.

What is Xarelto | Rivaroxaban 50 Mg used for?


XARELTO is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (1.1) for the treatment of deep vein thrombosis (DVT) (1.2) for the treatment of pulmonary embolism (PE) (1.3) for the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months (1.4) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery (1.5) in combination with aspirin, to reduce the risk of major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months. 1.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery. 1.6 Reduction of Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) XARELTO, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular (CV) death, myocardial infarction (MI) and stroke) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

I am breastfeeding mother and I am using Xarelto | Rivaroxaban 50 Mg. Can it have any bad effect on my kid? Shall I search for better alternative?

Xarelto | Rivaroxaban 50 Mg low risk for breastfeeding
Rivaroxaban is the one and only active ingredient present in Xarelto | Rivaroxaban 50 Mg. Rivaroxaban in itself is a low risk drug for lactation so it is easy to understand that Xarelto | Rivaroxaban 50 Mg also comes in category of Low Risk item while breastfeeding. Below is the summary of Rivaroxaban in breastfeeding.

Xarelto | Rivaroxaban 50 Mg Breastfeeding Analsys


Rivaroxaban while Breastfeeding

Low Risk

Direct factor Xa inhibitor, indicated in the prevention of thromboembolism.Administered orally every 12 to 24 hours. From a single published case study we know that it is excreted in breast milk in clinically insignificant amounts (Wiesen 2016); the newborn was not breastfed. Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.


Xarelto | Rivaroxaban 50 Mg Breastfeeding Analsys - 2


Rivaroxaban while Breastfeeding

CAS Number: 366789-02-8

Limited information indicates that a maternal dose of rivaroxaban of 30 mg daily produces low levels in milk. If rivaroxaban is required by the mother, it is not a reason to discontinue breastfeeding. However, until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[1][2]


Xarelto | Rivaroxaban 50 Mg and breastfeeding

I already used Xarelto | Rivaroxaban 50 Mg and meanwhile I breastfed my baby should I be concerned?

During whole lactation period you shall first discuss with your doctor and then together you shall decide whether you shall take that drug or not however if you have already taken Xarelto | Rivaroxaban 50 Mg then you shall inform your doctor, But you should not be worried too much as Xarelto | Rivaroxaban 50 Mg comes in category of low risk drug.


I am nursing mother and my doctor has suggested me to use Xarelto | Rivaroxaban 50 Mg, is it safe?

Though Xarelto | Rivaroxaban 50 Mg dose not comes in category of safe drugs rather it comes in category of low risk but if your doctor is aware that you are breastfeeding your baby and has still recommended it then its advantages must be outweighing the risks.


If I am using Xarelto | Rivaroxaban 50 Mg, will my baby need extra monitoring?

Not much


Who can I talk to if I have questions about usage of Xarelto | Rivaroxaban 50 Mg in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week